Biocon gets EIR from USFDA for its small particles API Unit in Bengaluru

Biocon gets EIR from USFDA for its small particles API Unit in Bengaluru

Overview

  • Post By : Kumar Jeetendra

  • Source: Capital Market - Live News

  • Date: 08 May,2020

Biocon has gotten the Establishment Inspection Report (EIR) from the U. S. Food and Drug Administration (FDA) for the Pre-Approval and GMP examination of its Small Molecules API Manufacturing Facility at Biocon Park SEZ, Bommansandra, Bengaluru, led between 20 January and 24 January 2020. At the finish of the review the office had given a Form 483, with five perceptions, which are being tended to by the Company. The EIR has been shut with a VAI arrangement for the perceptions.

About Author